1.Gore S, Mhamane S, Jadhav S, Padvi N, Mhatre A, Joshi P, Sawakare S, Samant V, Chaturvedi P, Pramesh CS, Gupta S, Budukh A. (2025) Implementation challenges of government-funded health schemes for cancer treatment at Tata Memorial Centre. Journal of Cancer Policy. 43:100564.

2. Rahman MM, Rahman MS, Islam MR, Gilmour S, Haruyama R, Budukh A, Shankar A, Mishra G, Mehrotra R, Matsuda T, Inoue M, Abe SK (2025). Regional variations and inequalities in testing for early detection of breast and cervical cancer: Evidence from a nationally representative survey in India. Journal of Epidemiology. 35(3):129-140

3. Chen X, Patkar N, Tembhare P, Papagudi S, Yeung C, Kanagal Shamanna R, Gujral S, Wood B, Naresh KN (2025). Fifth edition WHO classification: myeloid neoplasms. Journal of Clinical Pathology

4. Dalal N, Dhandapani H, Ingle A, Sharma D, Tayalia P. (2025) Functionalized Poly(ethylene Glycol) diacrylate scaffolds for In Situ immunomodulation of dendritic cells targeting melanoma tumor. ACS Biomaterials Science & Engineering

5. Jindal N, Patel K, Garg M, Mirgh S, Chichra A, Nayak L, Gokarn A, Punatar S, Bagal B, Mathew LJ, D'Silva S, Singh M, Khattry N (2025). High risk of graft rejection in patients with HLA homozygosity fFollowing haploidentical transplant using post-transplant xyclophosphamide. Blood Cell Therapy. 8(1):167–9.

6. Dev I, Puranik A, Trikalinos N, Girod B, Kim H, Prasad V (2025). Theranostics in lung neuroendocrine tumors. Seminars in Nuclear Medicine.

Book Chapters
1. Tamuli, B. Biswas S. (2025). A Comprehensive Methodology for Immortalizing Tumor-Infiltrating B Lymphocytes from Epithelial Cancers. In: Maity, PC (Ed). B-Cell Receptor Signaling. Methods in Molecular Biology, vol 2909. Humana, New York.Pp. 245-256.

2. Tamuli B., Ghagare, R., Mandal, G. (2025). Design, Production, and Optimization of Antigen-Specific Recombinant Antitumor Dimeric IgA Antibody. In: Maity, P.C. (Ed.) B-Cell Receptor Signaling. Methods in Molecular Biology, vol 2909. Humana, New York. Pp. 119-129

ClinGen is a National Institutes of Health (NIH)-funded resource dedicated to building a central resource that defines the clinical relevance of genes and variants for use in precision medicine and research

Cui Q, Li S, Liu X, Liu J, Chen W, Sheng Y, Xie P, Jin L, Zeng F, Lv F, Hu X, Xiao RP (2025). MIF-ACKR3 causes irreversible fat loss by impairing adipogenesis in cancer cachexia. Cell Metabolism.

In 1997, FDA approved Rituxan (rituximab), the first monoclonal antibody, to treat non-Hodgkin’s lymphoma.

2025 Advanced Centre for Treatment, Research and Education in Cancer (ACTREC)